Beta Bionics, Inc. (NASDAQ:BBNX – Get Free Report) insider Mark Hopman sold 30,779 shares of the stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $20.13, for a total value of $619,581.27. Following the transaction, the insider directly owned 56,479 shares in the company, valued at $1,136,922.27. The trade was a 35.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Mark Hopman also recently made the following trade(s):
- On Wednesday, September 9th, Mark Hopman sold 36,870 shares of Beta Bionics stock. The stock was sold at an average price of $18.46, for a total value of $680,620.20.
- On Wednesday, September 2nd, Mark Hopman sold 5,327 shares of Beta Bionics stock. The stock was sold at an average price of $19.11, for a total value of $101,798.97.
- On Wednesday, June 24th, Mark Hopman sold 1,258 shares of Beta Bionics stock. The shares were sold at an average price of $15.01, for a total value of $18,882.58.
Beta Bionics Stock Performance
BBNX stock opened at $21.89 on Friday. The company has a market cap of $984.83 million, a price-to-earnings ratio of -13.27 and a beta of 3.37. The business’s 50-day moving average is $17.66 and its two-hundred day moving average is $14.05. Beta Bionics, Inc. has a fifty-two week low of $8.80 and a fifty-two week high of $32.71.
Beta Bionics News Roundup
Here are the key news stories impacting Beta Bionics this week:
- Positive Sentiment: The FDA cleared Beta Bionics’ Mint patch pump, expanding its diabetes-device portfolio beyond the iLet Bionic Pancreas. A full U.S. launch is planned for the first quarter of 2027, potentially giving the company a second growth platform. Beta Bionics Stock Surges on FDA Clearance for Mint Patch Pump
- Positive Sentiment: Beta Bionics closed a public offering that generated $172.5 million in gross proceeds, including full exercise of the underwriters’ option. The capital should support Mint’s commercialization, manufacturing, research and development, and working capital needs. Beta Bionics Announces Closing of $172.5 Million Public Offering
- Positive Sentiment: Analyst sentiment remains broadly favorable. Recent price-target increases and a reported “Moderate Buy” consensus reflect optimism surrounding Mint and longer-term demand for automated insulin-delivery systems.
- Neutral Sentiment: Insiders Mark Hopman and Mike Mensinger sold shares under pre-arranged Rule 10b5-1 plans. The transactions totaled roughly $678,000 and do not necessarily indicate a change in management’s outlook, though they may affect sentiment. Beta Bionics Insider Trading
- Negative Sentiment: The equity offering issued millions of shares and pre-funded warrants at $17.25, creating dilution for existing shareholders and potentially limiting near-term upside.
- Negative Sentiment: Multiple law firms publicized a securities class action alleging inadequate disclosure of FDA Form 483 and warning-letter issues, including quality-management, patient-safety and customer-complaint concerns. The allegations remain unproven, but the litigation creates regulatory, reputational and financial uncertainty; the lead-plaintiff deadline is November 3, 2026. BBNX Securities Class Action Alert
- Negative Sentiment: Fiscal 2026 revenue guidance of $121 million to $126 million is below the approximately $133.9 million analyst consensus, signaling weaker near-term growth expectations.
Hedge Funds Weigh In On Beta Bionics
Several large investors have recently added to or reduced their stakes in BBNX. Perceptive Advisors LLC boosted its holdings in Beta Bionics by 39.8% in the 1st quarter. Perceptive Advisors LLC now owns 842,944 shares of the company’s stock worth $8,446,000 after buying an additional 240,000 shares during the period. BlackRock Inc. bought a new stake in Beta Bionics during the second quarter valued at about $52,340,000. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in shares of Beta Bionics in the fourth quarter valued at about $40,437,000. Bruce & Co. Inc. bought a new position in shares of Beta Bionics in the first quarter worth about $5,518,000. Finally, Y Intercept Hong Kong Ltd grew its position in shares of Beta Bionics by 4,236.8% during the first quarter. Y Intercept Hong Kong Ltd now owns 485,854 shares of the company’s stock worth $4,868,000 after purchasing an additional 474,651 shares in the last quarter.
Wall Street Analysts Forecast Growth
Several research analysts have weighed in on BBNX shares. Wall Street Zen upgraded shares of Beta Bionics from a “sell” rating to a “hold” rating in a research report on Saturday. UBS Group reissued a “buy” rating and set a $25.00 price objective on shares of Beta Bionics in a research report on Tuesday. Leerink Partners upped their price objective on Beta Bionics from $24.00 to $27.00 and gave the stock an “outperform” rating in a research note on Monday. Robert W. Baird raised their target price on Beta Bionics from $14.00 to $16.00 and gave the stock a “neutral” rating in a report on Tuesday. Finally, Weiss Ratings upgraded Beta Bionics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 18th. Seven analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Beta Bionics presently has an average rating of “Moderate Buy” and an average price target of $21.90.
Check Out Our Latest Analysis on Beta Bionics
Beta Bionics Company Profile
Beta Bionics, Inc is a medical technology company focused on developing automated insulin-delivery systems for people with diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to simplify diabetes management by using continuous glucose monitoring data to adjust insulin dosing with limited user input.
The iLet Bionic Pancreas received clearance from the U.S. Food and Drug Administration in 2023 for use by people with type 1 diabetes.
Featured Stories
- Five stocks we like better than Beta Bionics
- J.B. Hunt’s Stock Plunges After Market Misprices Profit Warning
- 2 Stocks Breaking Out Post-FOMC With One Thing in Common
- Lennar’s Q3 Miss Hides a Stronger Operating Story Beneath the Housing Slump
- These 3 Stocks Are Drawing Insider Buyers for Very Different Reasons
Receive News & Ratings for Beta Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beta Bionics and related companies with MarketBeat.com's FREE daily email newsletter.
